Gene editing may provide hope for the treatment of Fragile X, the leading genetic cause of autism.
Researchers have linked Fragile X and SHANK3 deletion syndrome, two disorders associated with autism, to specific microscopic walking patterns.
Researchers have identified a potential molecular mechanism that causes Fragile X syndrome in the developing fetal brain.
A new mouse study reveals a drug compound is effective at treating and potentially reversing symptoms of Fragile x syndrome.
Non-invasive auricular transcutaneous vagus nerve stimulation (atVNS), applied to an accessible area of the ear, improves memory in mouse models of intellectual disability.
Stem cell study reveals a genetic defect associated with fragile X syndrome delays the production of neurons during a critical stage of embryonic development.
Lovastatin, a common statin usually prescribed to control cholesterol, corrected learning and memory deficits associated with Fragile X syndrome in rodent models.
Researchers have identified a specific mechanism involved in how females inherit traits. The findings could help reduce susceptibility to Fragile X and Rett syndrome, the researchers report.
Researchers report functional alterations in L-type calcium channels were detected in models of Fragile X syndrome.
Researchers have successfully reduced some symptoms associated with fragile X syndrome in mice with the help of CRISPR-Cas 9 gene editing.
According to researchers, a drug approved by the FDA may reverse some of the symptoms associated with Fragile X syndrome. The drug can reverse hyper-excitability that leads to sensory hypersensitivity.
Researchers have derived purkinje cells from patients with TSC, a genetic syndrome that includes some ASD-like symptoms. The cells, researchers say, have several characteristics that could help explain how ASD develops at the molecular level.
